Table 1.

Study participant characteristics, genotypes, and delivery information (N=8)

Subject (Age)	BMI	Dosing Regimen	Sample Collection Times (GA**; PPA***)	CYP2B6 Genotype	CYP2C19 Genotype	Pertinent Medical Conditions	Co-medications	Time Since Last Dose Until Delivery	Delivery Information (GA**; MOD****)	Neonatal Weight(g); Placental Weight(g)
1 (28)	45.3	300 mg XL	T3 (34+0), PP (6+6)	*1/*1	*1/*1	Diabetes Smoker	Insulin Albuterol
2 (42)	42.9	450 mg XL	T2 (24+6), T3 (34+6), PP (6+2)	*1/*22	*1/*1	None	Risperidone
3 (35)	22.6	150 mg XL	T2 (27+6), T3 (35+1), PP (6+6), L&D	*1/*1	*1/*1	Diabetes	Insulin, Escitalopram Oxycodone	8 h	38+1 / VD	3864 / 1050
4 (35)	40.3	150 mg SR	T2 (28+6), PP (6+3)	*1/*1	*1/*1	Diabetes	Metformin
5 (28)	27.7	300 mg XL	T3 (34+0), PP (6+5)	*1/*6a	*1/*1	None	None
6 (38)	27.8	150 mg XL	T2 (26+6), T3 (34+1), PP (4+4)	*1/*6a	*1/*17	None	Levothyroxine
7 (30)	28.9	150 mg IR BID*	T2 (26+4), T3 (34+1), PP (12+5), L&D	*1/*2b	*1/*1	Diabetes Smoker	Insulin Progesterone Metoclopramide	11 h	34+3 / CD	2705 / 530
8 (36)	29.1	300 mg XL	T2 (26+2), PP (8+5), L&D	*2/*5b,c	*1/*1	Diabetes Renal insufficiencyd	Insulin Gabapentin Labetalol Fluoxetine Memantine	17 h	35+1 / CD	2547 / 485

BMI, body mass index; T2, second trimester; T3, third trimester; L&D, labor and delivery; PP, postpartum; VD, vaginal delivery; CS, cesarean delivery.

^{* =}Subject was taking IR dosing BID during her pregnancy, switched to once-daily dosing postpartum

^{** =}Gestational age, expressed as weeks + days

^{*** =}Postpartum age, expressed as weeks + days

^{**** =}Mode of delivery

^aCYP2B6*6 was assessed through 516G>T which may also be present in low frequency (<10%) variants including *9

^bCYP2B6*2 core mutation 681G>A can be detected in the CYP2B6*10 haplotype which was not examined in this cohort

^cCYP2B6*5 variant is defined by 1459C>T mutation, which is also present in the low frequency *7 haplotype

^dSubject 8 presented mild renal insufficiency, with serum creatinine of 0.96 mg/dL in T2 and 1.36 mg/dL PP.